Effect of an exercise bout before the booster dose of an inactivated SARS-CoV-2 vaccine on immunogenicity in immunocompromised patients

被引:2
|
作者
Gualano, Bruno [1 ,2 ]
Saad, Carla G. S. [3 ]
Sieczkowska, Sofia M. [1 ]
Lemes, Italo Ribeiro [1 ]
da Silva, Rafael Pires [1 ]
Pinto, Ana J. [1 ,4 ]
Mazzolani, Bruna C. [1 ]
Smaira, Fabiana, I [1 ]
Gil, Saulo [1 ]
Oliveira-Junior, Gersiel [1 ]
Aikawa, Nadia E. [3 ]
Medeiros-Ribeiro, Ana C. [3 ]
Silva, Clovis A. [3 ,5 ]
Yuki, Emily F. N. [3 ]
Pasoto, Sandra G. [3 ]
Pereira, Rosa Maria R. [3 ]
Shinjo, Samuel K. [3 ]
Andrade, Danieli C. O. [3 ]
Sampaio-Barros, Percival D. [3 ]
Roschel, Hamilton [1 ]
Bonfa, Eloisa [3 ]
机构
[1] Univ Sao Paulo, Fac Med FMUSP, Sch Phys Educ & Sport, Div Rheumatol,Appl Physiol & Nutr Res Grp, Sao Paulo, Brazil
[2] Univ Sao Paulo, Food Res Ctr, Sao Paulo, Brazil
[3] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, Div Rheumatol, Sao Paulo, Brazil
[4] Univ Colorado, Sch Med, Metab & Diabet & Anschutz Hlth & Wellness Ctr, Div Endocrinol, Anschutz Med Campus, Aurora, CO USA
[5] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, Inst Crianca & Adolescente,Pediat Rheumatol Unit, Sao Paulo, Brazil
基金
巴西圣保罗研究基金会;
关键词
COVID-19; immunosuppression; physical activity; resistance exercise; Sinovac-CoronaVac; ECCENTRIC EXERCISE; PHYSICAL-ACTIVITY; RESPONSES; EFFICACY; ANTIBODY; ADJUVANT;
D O I
10.1152/japplphysiol.00015.2022
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
This randomized controlled study aimed to investigate whether a single bout of exercise before the homologous booster dose of a SARS-CoV-2 inactivated vaccine could enhance immunogenicity in patients with spondyloarthritis. We selected 60 consecutive patients with spondyloarthritis (SpA). Patients assigned to the intervention group performed an exercise bout comprising three exercises. Then, they remained at rest for 1 h before vaccination. The control group remained at rest before vaccination. Immunogenicity was assessed before (Pre) and 1 mo after (Post) the booster using seropositivity rates of total anti-SARS-CoV-2 S1/S2 IgG, geometric mean titers of anti-S1/S2 IgG (GMT), frequency of neutralizing antibodies (NAb) positivity, and NAb activity. At Pre, 16 patients from the exercise group and 16 patients from the control group exhibited seropositivity for IgG (59% vs. 57.1%), and 1 mo after the booster dose, seropositivity occurred in 96% versus 100% of the cases. Only 10 patients from the exercise group and 12 patients from the control group showed positive NAb serology at Pre (37% vs. 42.8%). One month following the booster, NAb positivity was 96% versus 93%. GMT was comparable between groups at Pre. At Post, GMT increased similarly in both groups. Likewise, NAb activity was similar between groups at Pre and increased similarly in both of them as a result of the booster (47.5% vs. 39.9%). In conclusion, a single bout of exercise did not enhance immunogenicity to a homologous booster dose of an inactivated SARS-CoV-2 vaccine among patients with spondyloarthritis. NEW & NOTEWORTHY We tested the role of exercise as an adjuvant to a booster of a COVID-19 vaccine. Immunocompromised patients were immunized after an acute bout of exercise or not. Patients exhibited an excellent immunogenicity in response to
引用
收藏
页码:682 / 688
页数:7
相关论文
共 50 条
  • [21] Safety and immunogenicity of a tetravalent and bivalent SARS-CoV-2 protein booster vaccine in men
    Suad Hannawi
    Linda Saf Eldin
    Alaa Abuquta
    Ahmad Alamadi
    Sally A. Mahmoud
    Aala Hassan
    Shuping Xu
    Jian Li
    Dongfang Liu
    Adam Abdul Hakeem Baidoo
    Dima Ibrahim
    Mojtaba Alhaj
    Yuanxin Chen
    Qiang Zhou
    Liangzhi Xie
    Nature Communications, 14
  • [22] Safety and immunogenicity of a SARS-CoV-2 inactivated vaccine in patients with chronic hepatitis B virus infection
    Xiang, Tiandan
    Liang, Boyun
    Wang, Hua
    Quan, Xufeng
    He, Shengsong
    Zhou, Helong
    He, Yongwen
    Yang, Dongliang
    Wang, Baoju
    Zheng, Xin
    CELLULAR & MOLECULAR IMMUNOLOGY, 2021, 18 (12) : 2679 - 2681
  • [23] Effectiveness of an Inactivated SARS-CoV-2 Vaccine
    Wilder-Smith, Annelies
    Mulholland, Kim
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (10): : 946 - 948
  • [24] Safety and immunogenicity of a SARS-CoV-2 inactivated vaccine in patients with chronic hepatitis B virus infection
    Tiandan Xiang
    Boyun Liang
    Hua Wang
    Xufeng Quan
    Shengsong He
    Helong Zhou
    Yongwen He
    Dongliang Yang
    Baoju Wang
    Xin Zheng
    Cellular & Molecular Immunology, 2021, 18 : 2679 - 2681
  • [25] Safety and immunogenicity of a tetravalent and bivalent SARS-CoV-2 protein booster vaccine in men
    Hannawi, Suad
    Saifeldin, Linda
    Abuquta, Alaa
    Alamadi, Ahmad
    Mahmoud, Sally A.
    Hassan, Aala
    Xu, Shuping
    Li, Jian
    Liu, Dongfang
    Baidoo, Adam Abdul Hakeem
    Ibrahim, Dima
    Alhaj, Mojtaba
    Chen, Yuanxin
    Zhou, Qiang
    Xie, Liangzhi
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [26] Immunogenicity and Safety of an Inactivated Virus Vaccine Against SARS-CoV-2 in Patients with Autoimmune Rheumatic Diseases
    Medeiros-Ribeiro, Ana
    Aikawa, Nadia
    Schahin Saad, Carla Goncalves
    Vieira Neves Yuki, Emily Figueiredo
    Pedrosa, Tatiana do Nascimento
    Fusco, Solange
    Rojo, Priscila
    Pereira, Rosa
    Shinjo, Samuel
    Andrade, Danieli
    Sampaio-Barros, Percival
    Ribeiro, Carolina
    Deveza, Giordano
    de Oliveira Martins, Victor Adriano
    Silva, Clovis Artur
    Lopes, Marta
    Duarte, Alberto
    Antonangelo, Leila
    Sabino, Ester
    Kallas, Esper
    Pasoto, Sandra Gofinet
    Bonfa, Eloisa
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3260 - 3263
  • [27] Intradermal delivery of the third dose of the mRNA-1273 SARS-CoV-2 vaccine: safety and immunogenicity of a fractional booster dose
    Roozen, Geert V. T.
    Prins, Manon L. M.
    Prins, Corine
    Janse, Jacqueline J.
    Gruyter, Heidi L. M. de
    Pothast, Cilia R.
    Huisman, Wesley
    Koopman, Jan Pieter R.
    Lamers, Olivia A. C.
    Kuijer, Marjan
    Myeni, Sebenzile K.
    Binnendijk, Rob S. van
    den Hartog, Gerco
    Heemskerk, Mirjam H. M.
    Jochems, Simon P.
    Feltkamp, Mariet C. W.
    Kikkert, Marjolein
    Rosendaal, Frits R.
    Roestenberg, Meta
    Visser, Leo G.
    Roukens, Anna H. E.
    CLINICAL MICROBIOLOGY AND INFECTION, 2024, 30 (07) : 930 - 936
  • [28] Immunological evaluation of an mRNA vaccine booster in individuals fully immunized with an inactivated SARS-CoV-2 vaccine
    Xu, Xingli
    Liao, Yun
    Jiang, Guorun
    Yao, Weiguo
    Duan, Suqin
    Xiao, Kang
    Ding, Xuefeng
    Zhao, Heng
    Zhang, Yujian
    Zhang, Aihua
    Yang, Jingsi
    Che, Yanchun
    Zhang, Jun
    Zhao, Fanfan
    Ma, Xiaopin
    Zhao, Zhimei
    Cui, Pingfang
    Yang, Xiaolei
    Lin, Xiaorui
    Cai, Wei
    Yan, Jiao
    Yang, Zhenqing
    Qiu, Heng
    Zhang, Jing
    Huang, Lei
    Shen, Mingyun
    Zhao, Guofeng
    Yu, Li
    Li, Dandan
    Fan, Shengtao
    Zhang, Ying
    Wang, Lichun
    He, Licun
    Dong, Fei
    Xu, Wenbo
    Li, Hangwen
    Li, Qihan
    CLINICAL AND TRANSLATIONAL MEDICINE, 2022, 12 (06):
  • [29] CoronaVac: A review of efficacy, safety, and immunogenicity of the inactivated vaccine against SARS-CoV-2
    Jin, Lairun
    Li, Zhuopei
    Zhang, Xiaoyin
    Li, Jingxin
    Zhu, Fengcai
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (06)
  • [30] Immunogenicity of SARS-CoV-2 vaccine in patients with multiple myeloma
    Malard, Florent
    Gaugler, Beatrice
    Gozlan, Joel
    Bouquet, Lucie
    Fofana, Djeneba
    Van De Wyngaert, Zoe
    Ikhlef, Souhila
    Marjanovitch, Zora
    Morand-Joubert, Laurence
    Mohty, Mohamad
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S117 - S117